Targeted Immunotherapies for Cancer | SRI International
This is an archived website. Go to the current SRI website

Toggle Menu
A peptide that targets dendritic cells delivers quantum dots intracellularly.

Targeted Immunotherapies for Cancer

SRI's Brown Laboratory is taking multiple approaches to develop effective anti-cancer immunotherapies.

Recently, much effort has been placed on harnessing the power of the patient’s immune system to recognize and destroy tumor cells, in the same fashion that the immune system neutralizes infectious pathogens.

To develop effective anti-cancer immunotherapies, SRI's Brown Laboratory is taking multiple approaches. We are developing strategies to deliver antigens to specialized antigen presenting cells of the immune system to generate a rapid and robust immune response against tumors.

The laboratory is also developing a novel non-viral therapy designed to generate a secondary immune response toward the tumor bypassing the need to identify a tumor antigen or educate the immune system.

Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number R01CA164447. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.